THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (Nasdaq: RPRX) announced today that it has established an at-the-market program through which it may sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to $10 million. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE Amex: LTS), is acting as sales agent on the program. Based upon regulatory limitations, Repros estimates that it will be limited to selling no more than approximately $7.8 million worth of its shares at this time, due to the Company’s estimate of its current public float.
